Cullinan Therapeutics, Inc. Common Stock
CGEM US2300311063
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -48% | -36% | -5% | 15% | 2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Sumer Jacquelyn L CLO |
8.53 USD |
3,756 Sold |
32,039 USD |
25/02/2025 | 25/02/2025 |
| Jones Jeffrey Alan CMO |
8.53 USD |
4,895 Sold |
41,754 USD |
25/02/2025 | 25/02/2025 |
| Ahmed Nadim CEO |
8.53 USD |
12,529 Sold |
106,872 USD |
25/02/2025 | 25/02/2025 |
| Michaelson Jennifer CSO |
8.53 USD |
3,756 Sold |
32,039 USD |
25/02/2025 | 25/02/2025 |
| Michaelson Jennifer CSO |
12.51 USD |
4,000 Sold |
50,040 USD |
06/01/2025 | 06/01/2025 |
| Ahmed Nadim CEO |
11.87 USD |
8,400 Sold |
99,708 USD |
24/12/2024 | 24/12/2024 |
| Jones Jeffrey Alan CMO |
11.41 USD |
4,632 Sold |
52,851 USD |
18/12/2024 | 18/12/2024 |
| Michaelson Jennifer CSO |
11.41 USD |
4,693 Sold |
53,547 USD |
18/12/2024 | 18/12/2024 |
| Sumer Jacquelyn L CLO |
11.41 USD |
3,482 Sold |
39,730 USD |
18/12/2024 | 18/12/2024 |
| Michaelson Jennifer CSO |
12.52 USD |
3,489 Sold |
43,682 USD |
12/12/2024 | 12/12/2024 |